Phalguni Deswal
@Phalguni_GD
ANS-858 is an investigational selective and reversible ALDH2 inhibitor, which has been reported to reduce craving and drug-seeking behaviour in preclinical studies. Image Credit: Axel Bueckert / Shutterstock.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) in the US has awarded a $2m grant to Amygdala Neurosciences to support investigational new drug (IND) application and early development of the aldehyde dehydrogenase (ALDH2) inhibitor for the treatment of alcohol use disorder.
According to the 2021
survey by the NIAAA
, 29.5 million people aged 12 years and older have experienced
alcohol use disorder
. Current treatments include behavioural therapy, medication, support groups, and counselling.
Recommended Reports
Reports
LOA and PTSR Model - Nov-DB2 in Type 2 Diabetes
GlobalData
Reports
LOA and PTSR Model - Semaglutide in Type 2 Diabetes
GlobalData
View all
Companies Intelligence
Novo Nordisk AS
Clearmind Medicine Inc
Amygdala Neurosciences Inc
View all
ANS-858 is an investigational selective and reversible
ALDH2 inhibitor
, which has been reported to reduce craving and drug-seeking behaviour in preclinical studies.
Amygdala CEO Brent Blackburn said in the
press release
: “This award will enable the development of ANS-858 through pre-clinical evaluation required of an investigational new drug (IND) application to the FDA.”
There are multiple drugs currently in development for treating alcohol use disorder. These mainly investigate the
use of psychedelic compounds
, including
Beckly Psytech’s Phase IIa trial
(NCT05674929) for BPL-003, and
Clearmind Medicine’s Phase I/II trial
for CMND-100.
Other ALDH2 targeting drugs currently in development include
Novo Nordisk
’s
NN-6020 small interfering RNA
(siRNA) compound in Phase I.
As per GlobalData’s analysis of the
alcohol use disorder competitive landscape
, the disease market is highly genericised. Furthermore, the drug pipeline is mostly early staged, with only 1.5% of drugs in Phase III. The late-stage pipeline drugs include R-Pharm’s odelepran currently in pre-registration, and Phase III
Adial Pharmaceuticals’ ondansetron hydrochloride
.
GlobalData is the parent company of
Pharmaceutical Technology
.
